Article
Pharmacokinetics-Based Adjusted Versus Standard Dose of Ribavirin Does Not Improve Virologic Response Rates in Chronic Hepatitis C Genotype 4 Patients: A Randomized Controlled Trial.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research - 1 Nov 2017
Altraif Ibrahim H, Sanai Faisal, Babatin Mohammed A, Alalwan Abduljaleel A, Abdo Ayman A, Alhamoudi Waleed, Peedikayil Musthafa, Alghamdi Hamdan, Alsohaibani Fahad, Alswat Khalid A, Murtaza Shazia, Alghamdi Abdullah, Altraif Sara, Aljumah Abdulrahman, Handoo Fayaz A, AlBekairy Abdulkareem M, Al-Ashgar Hamad I, Alquaiz Mohammed, Alblawi Mohammed A, AlTamimi Waleed, Loustaud-Ratti Véronique, Marquett Pierre
Abstract excerpt
Optimal doses of Ribavirin (RBV) for hepatitis C virus (HCV) treatment are not known. To assess the safety and efficacy of PegIFNalfa-2a in combination with an adjusted (ADJ) RBV dose based on early pharmacokinetics versus a fixed standard (STD) dose of RBV in chronic HCV genotype (GT) 4-naive patients in a randomized trial. One hundred eighty-one patients were randomized. The baseline variables were similar in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.